🔗 Share this article

An underground economy for unapproved slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, according to recent findings.

Investigational Drug Gaining Popularity Online

Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed weight-reducing effects. Followers are urged to message these accounts directly for source information, while also obtaining promotional offers.

Thriving Commerce on Messaging Platforms

Separately, a flourishing trade exists on Telegram, where groups with thousands of members share “before and after” images, injection guides and claims of rapid British shipping. Vendors promote the substance there before redirecting customers to WhatsApp for transactions.

Learning About Retatrutide

Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies indicate it could assist patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the next Ozempic.

Healthcare Experts Express Concerns

However, doctors and pharmacists have cautions that the distribution of what is still an unlicensed drug in the UK is worrisome and could lead to individuals administering products of unknown origin.

Some experts stated the popularity for retatrutide could be linked to the rising price of licensed weight loss products such as Mounjaro.

Legal Position and Implementation

Marketing the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unapproved drug that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.

Several influencers try to circumvent the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and distribution can still breach medicines, advertising, and customer regulations, risking fines, prosecution or imprisonment.

Platform Response and Content Removal

Based on the social media company, the platform has removed violative material and banned associated keywords and query recommendations. The company stated it was committed to keeping the platform safe and investing in strengthening compliance measures.

Digital Trading Activities

Research also discovered communities with up to nine thousand members marketing retatrutide using the platform's integrated search feature, which operates like a online catalog. Entering “retatrutide” immediately brings up groups with numerous of members, filled with photos of slimming results, positive testimonials and detailed instructions for preparing or administering at residence.

Within minutes of entering one community, a vendor shared contact information, where the majority of transactions occur. The vendor sent an instruction manual and guaranteed shipping within two days. When asked whether the product was authentic, one vendor responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None inquired about body mass, medical conditions or past usage.

Item Information and Costs

Inside these communities, posts display black plastic parcels with postal service stickers, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, prepared at home with purified liquid, or ready-to-use pens usually priced at £160 for 20 milligrams. When asked how long a pen should be used, sellers give contradictory responses ranging from a several days to “depends on your body”.

Service Oversight and Security Actions

A representative for the messaging service said it regularly moderated dangerous content on its platform including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“People are injecting substances they can’t verify. Although the research behind retatrutide is valid, these online products may not contain what they advertise,” said a pharmacy expert, the head of pharmacy at Chemist4U.

A medical professional of an online medical service connected the surge in interest to recent cost increases for authorized slimming medications such as Mounjaro. “With prices increasing, patients are using online platforms. But fake treatments are extremely dangerous. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she said.

Her staff has previously seen individuals injured by self-injection from unconfirmed suppliers. “We understand the frustration, but purchasing from messaging apps or WhatsApp is gambling with your well-being,” said the doctor. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Statement

A spokesperson from the pharmaceutical company stated retatrutide was in phase 3 research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they said, adding that any product “misleadingly claiming itself as a company investigational product not yet authorized … may expose users to potentially serious health risks”.